Bausch + Lomb (BLCO) said Wednesday it obtained European CE Mark approval for its LuxLife vision intraocular lens.

The LuxLife intraocular lens allow surgeons to treat the 79.5% of people with more than 0.5D of corneal astigmatism before cataract surgery, the company said.

The LuxLife intraocular lens will be commercially available in Europe in the coming weeks, Bausch + Lomb said.

The company's shares were rising 1% in recent trading.

Price: 11.03, Change: +0.13, Percent Change: +1.19